Aksharam Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 4.00 Cr
as on 16-11-2024
- Company Age 6 Year, 30 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.51 Cr
as on 16-11-2024
- Revenue 26.02%
(FY 2023)
- Profit 130.74%
(FY 2023)
- Ebitda 201.05%
(FY 2023)
- Net Worth 133.21%
(FY 2023)
- Total Assets 13.65%
(FY 2023)
About Aksharam Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 4.00 Cr.
The company currently has active open charges totaling ₹7.51 Cr.
Piyushkumar Jesadia, Ghanshyam Adalja, Jitendra Agrawal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24299GJ2018PTC105276
- Company No.
105276
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Nov 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aksharam Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Piyushkumar Jesadia  | Director | 22-Nov-2018 | Current |
| Ghanshyam Adalja | Director | 22-Nov-2018 | Current |
| Jitendra Agrawal | Director | 22-Nov-2018 | Current |
| Hiteshbhai Jesadiya | Director | 22-Nov-2018 | Current |
Financial Performance of Aksharam Pharma.
Aksharam Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 26.02% increase. The company also saw a substantial improvement in profitability, with a 130.74% increase in profit. The company's net worth Soared by an impressive increase of 133.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aksharam Pharma?
Unlock access to Aksharam Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Palco E-Waste Recyclers Private LimitedActive 13 years 10 monthsJitendra Agrawal is a mutual person
Shape Pharma Private LimitedActive 12 years 8 monthsPiyushkumar Jesadia, Jitendra Agrawal and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 24 Oct 2019 | ₹7.51 Cr | Open |
How Many Employees Work at Aksharam Pharma?
Aksharam Pharma has a workforce of 25 employees as of Aug 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aksharam Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aksharam Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
